Abstract
miR-21 and let-7 are two of the most studied microRNAs (miRNAs), as the former is the most frequently upregulated and the latter is the most frequently down-regulated in cancer. In this short essay, we examine the convergence of miR-21 and let-7 in two major cancer pathways: Ras and NF-κB. miR-21 suppresses multiple targets to enhance the oncogenic action of Ras, while let-7 is a direct negative regulator of the Ras gene family. let-7 is proposed to repress the activation of NF-κB through down-regulation of Ras and IL-6, while miR-21 is demonstrated to enhance NF-κB activation by down-regulating Pten and thereby increasing the activity of Akt, a kinase known to promote the NF-κB pathway. Therefore, miR-21 and let-7 contravene each other in cancer and simultaneous targeting of both is an attractive therapeutic strategy against cancers exhibiting both Ras mutations and constitutive NF-κB activation.
Keywords: MicroRNA, Cancer, miR-21, let-7, Ras, NF-kB, oncogenic action, apoptosis, pathobiological, phylogenetic.
MicroRNA
Title:miR-21 and let-7 in the Ras and NF-κB Pathways
Volume: 1 Issue: 1
Author(s): Saibyasachi N. Choudhury and Yong Li
Affiliation:
Keywords: MicroRNA, Cancer, miR-21, let-7, Ras, NF-kB, oncogenic action, apoptosis, pathobiological, phylogenetic.
Abstract: miR-21 and let-7 are two of the most studied microRNAs (miRNAs), as the former is the most frequently upregulated and the latter is the most frequently down-regulated in cancer. In this short essay, we examine the convergence of miR-21 and let-7 in two major cancer pathways: Ras and NF-κB. miR-21 suppresses multiple targets to enhance the oncogenic action of Ras, while let-7 is a direct negative regulator of the Ras gene family. let-7 is proposed to repress the activation of NF-κB through down-regulation of Ras and IL-6, while miR-21 is demonstrated to enhance NF-κB activation by down-regulating Pten and thereby increasing the activity of Akt, a kinase known to promote the NF-κB pathway. Therefore, miR-21 and let-7 contravene each other in cancer and simultaneous targeting of both is an attractive therapeutic strategy against cancers exhibiting both Ras mutations and constitutive NF-κB activation.
Export Options
About this article
Cite this article as:
N. Choudhury Saibyasachi and Li Yong, miR-21 and let-7 in the Ras and NF-κB Pathways, MicroRNA 2012; 1 (1) . https://dx.doi.org/10.2174/2211536611201010065
DOI https://dx.doi.org/10.2174/2211536611201010065 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Revolutionizing Animal Farming: The Impact of miRNAs on Health and Productivity
The utilization of microRNAs (miRNAs) in animal production represents an emerging frontier in agricultural biotechnology, with the potential to revolutionize the sector. MiRNAs, small non-coding RNA molecules, play a crucial role in regulating gene expression, influencing vital processes such as growth, muscle development, disease resistance, and feed efficiency. Their application ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiopharmaceuticals to In Vivo Characterize Adrenal Incidentalomas:The Integrated Role of Radionuclide and Radiological Techniques
Current Radiopharmaceuticals Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Current Gene Therapy Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Current Drug Targets Correlation between in vitro and in vivo Data of Radiolabeled Peptide for Tumor Targeting
Mini-Reviews in Medicinal Chemistry Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
Current Pharmaceutical Design A Case Report of Non-puerperal Uterine Inversion
Current Women`s Health Reviews Targeting the Assembly of the Human Immunodeficiency Virus Type I
Current Pharmaceutical Design The Therapeutic Target Hsp90 and Cancer Hallmarks
Current Pharmaceutical Design Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Thymic Immunosuppressive Pentapeptide (TIPP) Shown Anticancer Activity in Breast Cancer and Chronic Myeloid Leukemia Both <i>In Vitro</i> and <i>In Vivo</i>
Protein & Peptide Letters Asymmetric Syntheses Based on Organocatalysis
Mini-Reviews in Organic Chemistry Identification of Uptake Mechanism of Cell-Penetrating Peptides by their Polar Profile
Current Bioinformatics RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Editorial (Hot Topics: Naturally Occurring Molecules and Anticancer Combination Therapies in the Era of Personalized Medicine and Economic Crisis)
Current Pharmaceutical Design Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy